Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637371 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
A Phase 1 study of Asthma, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 16
- Study locations
NCT06637371: Recruiting Phase 1 study of Asthma, sponsored by Amgen.
NCT06637371 is a Phase 1 study of Asthma that is actively recruiting participants, run by Amgen. The registered enrollment target is 124 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06637371, a Phase 1 study of Asthma, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. Serious AEs (SAEs) are defined as any untoward medical occurrence that, meet at least 1 of the following serious criteria: Immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or signif
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 691
Study Locations (16)
Other
- Algemeen Ziekenhuis Sint Maarten-Emmaus vzw - Mechelen
- VPD Heart and Lung Research Institute - Cambridge
- Chelsea and Westminster Hospital - London
- The Medicines Evaluation Unit - Manchester
Florida
- Translational Clinical Research LLC - Aventura
- Destiny Research Center - Palmetto Bay
Minnesota
- Mayo Clinic - Rochester
- Prism Research LLC dba Nucleus Network - Saint Paul
North Carolina
- University of North Carolina Clinical and Translational Research Center - Chapel Hill
- North Carolina Clinical Research - Raleigh
California
- Orange County Research Center - Lake Forest
Georgia
- ClinCept, LLC - Columbus
Massachusetts
- Brigham and Womens Hospital - Boston
Texas
- Endeavor Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2027-06-07 |
| Phase | Phase 1 |
What NCT06637371 shows while recruiting
NCT06637371 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06637371 lists 16 locations in 10 states (Other, Florida, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06637371 about?
NCT06637371 is a clinical study titled "A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma". The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
What is the current status of trial NCT06637371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2024-10-16. Estimated completion is 2027-06-07.
What conditions does trial NCT06637371 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06637371?
The interventions under investigation include: Placebo (DRUG), AMG 691 (DRUG).
Who is sponsoring clinical trial NCT06637371?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06637371 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06637371's enrollment target sits among peer trials
124 197th of 374 higher than 178 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI